OBIO · Orchestra BioMed Holdings, Inc.
$5.49
+0.06 (+1.01%)
At close · Aug 21
Market Cap
$333.58M
Shares
60.11M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eric Rose | Board | Resigned | 2025-02-05 |
| Chris Cleary | Class II director | Appointed | 2025-02-05 |
| John Mack | Class I director | Appointed | 2024-07-30 |
| Andrew Taylor | Chief Financial Officer | Appointed | 2023-06-08 |
| Bill Little | Executive Vice President of Corporate Development and Strategy | Appointed | 2023-06-08 |
| Andrew Taylor | Chief Financial Officer | Appointed | 2023-06-08 |
| Michael Kaswan | Chief Financial Officer | Resigned | 2023-06-08 |
| Michael D. Kaswan | Chief Financial Officer | Appointed | 2023-01-31 |
| Yuval Mika, Ph.D. | General Manager and Chief Technology Officer, Bioelectronic Therapies | Appointed | 2023-01-31 |
| Darren R. Sherman | President and Chief Operating Officer | Appointed | 2023-01-31 |
| David P. Hochman | Chief Executive Officer | Appointed | 2023-01-31 |
| Eric S. Fain, M.D. | Class III director | Appointed | 2023-01-31 |
| David P. Hochman | Class III director | Appointed | 2023-01-31 |
| Darren R. Sherman | Class III director | Appointed | 2023-01-31 |
| Geoffrey W. Smith | Class II director | Appointed | 2023-01-31 |
| Pamela Y. Connealy | Class II director | Appointed | 2023-01-31 |
| Jason Aryeh | Class I director | Appointed | 2023-01-31 |
| Eric A. Rose, M.D. | Class I director | Appointed | 2023-01-31 |
Key facts
CIK
1814114
CUSIP
68572M106
13F (30d)
72 filings
72 filers
Visit website
Investor relations